Immunosuppressant-induced cutaneous drug reactions in solid organ transplant recipients

Identifying risk factors for cutaneous disease among solid organ transplant recipients: A retrospective review

“… 3 , 8 Within 4 years after transplantation, infectious and inflammatory conditions comprise >50% of cutaneous complications. 9 , 10 It is common for the reactivation of latent viruses, such as human herpes virus 6, human papillomavirus, and cytomegalovirus, to contribute. 8 , 11 , 12 , 13 , 14 Although some conditions, such as psoriasis, are less common because of immunosuppressive drug regimens, other inflammatory lesions, such as acneiform eruptions and dermatitis, occur with increased frequency.…”

“… 8 , 11 , 12 , 13 , 14 Although some conditions, such as psoriasis, are less common because of immunosuppressive drug regimens, other inflammatory lesions, such as acneiform eruptions and dermatitis, occur with increased frequency. 6 , 9 , 15 Both inflammatory and infectious conditions have the potential to affect quality of life and subsequent adherence to chronic immunosuppressive therapy. 16 , 17 …”

The translation and validation of the Organ Transplant Symptom and Well-Being Instrument in China

“…HRQOL in organ transplant recipients has been extensively assessed since it emergence as an important outcome for measuring the long-term success of transplants [6][7][8][9][10]. Previous research on the quality of life as it relates to organ transplantation primarily includes the quality of life of the long-term survival of patients following transplantation [10][11][12][13][14][15][16], the effect of compliance with immunosuppressive drugs as it relates to the quality of life [17][18][19][20][21], and other influencing factors of quality of life in patients following transplantation [4,[22][23][24]. The most common tool for measuring the quality of life of patients following an organ transplant is the Short Form 36 (SF-36) [25][26][27][28][29], however, it is less sensitive to disease-specific HRQOL issues.…”